Baclofen in Personal Injury Claims

Navigate muscle relaxant use, dependence risk, and recovery goals

Published: 3 April 2026 | Updated: 3 April 2026

Baclofen and Musculoskeletal Injury Recovery

Baclofen is a gamma-aminobutyric acid (GABA) agonist prescribed for muscle spasticity and rigidity, commonly encountered in personal injury claims involving spinal cord injury, traumatic brain injury, or significant musculoskeletal trauma. Unlike some muscle relaxants, baclofen has legitimate neurological indication and documented efficacy. However, in your claims context, baclofen use often extends beyond evidence-based parameters: doses escalate, concurrent CNS depressants accumulate, and dependence risk emerges. For insurers, the challenge is distinguishing appropriate baclofen use from dose creep and inappropriate deprescribing. This article equips you to manage baclofen use in claims without either underfunding genuine spasticity treatment or allowing indefinite dose escalation and polypharmacy.

Baclofen Pharmacology and Clinical Use

Baclofen acts as a GABA-B receptor agonist in the spinal cord and brain, reducing motor neuron excitability and thus muscle tone. It's indicated for spasticity from multiple sclerosis, spinal cord injury, stroke, or traumatic brain injury. Oral dosing ranges typically from 15mg to 80mg daily, divided into three doses. Some claimants with severe spasticity may require higher doses, though diminishing returns and adverse effects increase at 80mg daily and above.

Unlike benzodiazepines, baclofen's mechanism is specific to spasticity reduction; it's not a non-specific CNS depressant. This specificity is theoretically advantageous, but in practice, baclofen does cause drowsiness, dizziness, and fatigue, particularly at higher doses or when combined with other CNS agents.

Dependence and Tolerance

Baclofen develops tolerance with prolonged use. Claimants initially well-controlled at 20mg three times daily may report loss of efficacy after 6 to 12 months, prompting dose escalation. However, increasing doses of an ineffective regimen often worsens side effects (sedation, cognitive dulling) without restoring symptom control. This pattern suggests tolerance rather than inadequate initial dosing and typically signals need for review, not escalation.

Physical and Psychological Dependence

Abrupt baclofen cessation after prolonged use causes withdrawal: rebound spasticity, autonomic instability, hallucinations, and seizures. Physical dependence is genuine. Psychological dependence also occurs; claimants become convinced spasticity management depends absolutely on baclofen. Some develop nocebo expectations, expecting worsening despite medical optimization. In your claims context, this means any deprescribing must be gradual, planned, and coordinated with spasticity management alternatives.

Baclofen in Polypharmacy and CNS Depression

Baclofen combined with opioids, benzodiazepines, sedating antidepressants, or other CNS depressants significantly amplifies sedation, cognitive impairment, and overdose risk. Many claims involve precisely this scenario: pain managed with opioids, spasticity with baclofen, anxiety with benzodiazepines. The cumulative CNS depression often derails rehabilitation and work-return progress.

Your review should identify baclofen plus CNS depressants as a deprescribing priority. Often, one agent can be reduced or ceased while maintaining therapeutic benefit of another. For instance, reducing baclofen while optimizing opioid analgesia, or switching from benzodiazepine to SSRI for anxiety, can reduce overall CNS depression.

Appropriate Use vs. Overuse

Monitoring and Assessment

Objective Spasticity Assessment

Don't rely on claimant report alone. Objective assessment includes:

• Modified Ashworth Scale: Graded assessment of muscle tone (0 to 4 scale)
• Functional measures: Ability to walk, transfer, perform ADLs
• Pain or contracture risk: Spasticity that protects against contracture or pain may warrant treatment; asymptomatic spasticity might not
• Work-relatedness: Does spasticity impair return-to-work capacity, or is functional loss from side effects rather than spasticity?

Baclofen Alternatives and Adjuncts

When Baclofen Monotherapy Plateaus

If baclofen efficacy diminishes or side effects limit dosing, consider adjunctive agents rather than monotherapy escalation:

• Tizanidine: Alpha-2 adrenergic agonist; less sedating than baclofen; good adjunct. Monitor for liver toxicity.
• Dantrolene: Acts directly on muscle; different mechanism than baclofen; combines well. Risk of hepatotoxicity; monitor LFTs.
• Gabapentin: Often used for neuropathic pain and spasticity adjunct. Safe; minimal hepatic metabolism.
• Intrathecal baclofen (pump): Direct spinal cord delivery; allows much lower systemic doses. Indicated for severe spasticity refractory to oral therapy.

Deprescribing Baclofen

If baclofen is identified as inappropriate (prescribed for non-spastic pain, or causing intolerable side effects), deprescribing must be slow. Abrupt cessation risks rebound spasticity and withdrawal symptoms. Taper over 1 to 2 weeks minimum; longer if dose is high.

Insurer Governance: Baclofen Protocol

• Indication verification: Approve baclofen only for documented spasticity from neurological injury. Request assessment of spasticity severity; don't accept "pain" as indication alone.
• Initial dosing: Approve typical range (15 to 40mg daily) without pre-authorization. Beyond 40mg daily, request justification and spasticity reassessment.
• Every 6 months: Request reassessment confirming ongoing spasticity, documented response to baclofen, and functional benefit.
• Polypharmacy review: Any baclofen combined with opioids and benzodiazepines triggers deprescribing discussion; prioritize reducing CNS depression.
• Dose escalation: Any increase beyond 40mg daily requires prescriber justification and objective spasticity reassessment. Consider alternatives before further escalation.
• Side effects: If claimant reports sedation, cognitive impairment, or weakness, mandate review. Optimize dose or consider adjunctive agent.

Return-to-Work Considerations

Baclofen's sedating effects have direct implications for return-to-work. A claimant on baclofen 60mg daily may be cognitively impaired or fatigued. Assess work-readiness explicitly: is sedation from appropriate baclofen dosing, or from overtreatment? Can dose be reduced while maintaining spasticity control? Is the claimant safe to return to previous role, or does role modification required? Premature return-to-work on high-dose baclofen courts safety risk and potential reinjury.